Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: The Roman experience

Carlo Pozzilli, L. Prosperini, E. Sbardella, L. De Giglio, E. Onesti, V. Tomassini

Research output: Contribution to journalArticle

Abstract

Safety, tolerability and efficacy profiles of interferon beta (IFNβ) therapy in relapsing multiple sclerosis (MS) has been widely verified both in trial settings and in daily clinical practice. However, for a variable percentage of treated patients, it remains only partially effective. In this study, we reported the post-marketing experience of the efficacy of IFNβ therapy for a large cohort of MS patients regularly attending the MS Outpatient Clinic of "La Sapienza University" in Rome. In this cohort we also sought clinical and paraclinical variables responsible for the clinical course of MS during IFNβ therapy. Patients that received treatment with one of the IFNβ formulations for at least 1 year were included. Clinical outcomes (i. e., relapses and disability score) were monitored throughout the entire study period. Magnetic resonance imaging (MRI) scans were performed twice for each subject: at baseline and after 1 year of therapy. The occurrence of more than one relapse during the study period or a sustained disability progression in the Expanded Disability Status Scale (EDSS) score were considered as criteria for the definition of suboptimal clinical response to IFNβ therapy. During IFNβ therapy (number of patients 242, mean length of treatment 4.3±2.3 years) a reduction in the annualised relapse rate of 59% (p

Original languageEnglish
JournalNeurological Sciences
Volume26
Issue numberSUPPL. 4
DOIs
Publication statusPublished - Dec 2005

Keywords

  • Disability progression
  • Interferon beta
  • MRI
  • Multiple sclerosis
  • Predictors of response
  • Relapse rate

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: The Roman experience'. Together they form a unique fingerprint.

  • Cite this